-
Study aim
-
To determine if the addition of hydrocortisone, thiamine and ascorbic acid to standard care versus standard care in septic shock confers an in-hospital and 28-day mortality benefit
-
Design
-
A triple blinded, randomized, parallel clinical trial with control group
-
Settings and conduct
-
A multi-center (Baqiyatallah, Sina, Shariati, Imam khomeini, and Masih daneshvari hospitals in Tehran and Besat hospital in Hamadan), triple-blinded (Patient, data collector researcher, and statistician), two groups (intervention and control) clinical trial will be conducted by convenience sampling and then, random allocation using four-block in suffering hospitalized patients in medical and surgical (general) intensive care unit from septic shock. In the intervention group, patients will receive three hydrocortisone, thiamine, and ascorbic acid drugs along with routine treatment and the control group will receive routine treatment.
-
Participants/Inclusion and exclusion criteria
-
Inclusion Criteria
• Septic shock
• Age ≥ 18 years
Exclusion Criteria
• Age < 18 years
• Pregnant
• Patients with limitation of care (i.e. do not resuscitate [DNR])
• Known Glucose-6-Phosphate Dehydrogenase (G6PD)Deficiency
• Excluding primary admission diagnosis including the following: acute stroke; acute coronary syndrome; active gastrointestinal bleed; burn; trauma
• Vasopressor use prior to randomization for more than 24 hours
-
Intervention groups
-
Intervention group: Receiving three drugs hydrocortisone, thiamine and ascorbic acid along with standard care and Control group: Receiving standard care
-
Main outcome variables
-
Primary: 28-day mortality rate
Secondary:
(1) More rapid improvements in illness severity
(2) Greater changes in biochemical profiling
(3) Improved hospital stay metrics